2843 E. Grand River Avenue – #230 East Lansing, MI 48823 [email protected] 303-783-0924

Clinical Trial News

Clinical Trial Information


Targeting cancer drugs to gene abnormalities


From the National Cancer Institute (NCI)  –  a NCI-MATCH Clinical Trial to link targeted cancer drugs to gene abnormalities.  This is a molecular analysis for therapy choice.  The Trial will seek to determine whether targeted therapies for patients whose tumors have specific gene mutations will be effective regardless of their cancer types.


NCI-Match will incorporate more than 20 different study drugs or drug combinations, each targeting a specific gene mutations in order to match each patient in the trial with a therapy that targets a molecular abnormality in her or his tumor.


Enrollment in the NCI-MATCH will be available across the country through NCTN sites and will also be available through sites nationwide that participate in the NCI Community Oncology Research Program – 2,400 sites can participate in the Trial.


This is a hopeful research focus for the future.

For more detailed information, go to:  http://www.cancer.gov/news-events/press-releases/2015/nci-match.


The NCI offers a LIVE HELP ONLINE CHAT Monday-Friday 8 am – 11 pm EST:

1 -800-422-6237.


Questions? [email protected]